Conserved 5' Terminal Stem-Loop in NORAD Enables ASO-Mediated Restoration of Genomic Stability

Target: NORAD Composite Score: 0.647 Price: $0.65 Citation Quality: Pending molecular biology Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

⚠ Missing Evidence⚠ Low Validation Senate Quality Gates →

Quality Report Card click to collapse

Composite: 0.647

Top 44% of 984 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

B+ Mech. Plausibility 15% 0.70 Top 44%

B+ Evidence Strength 15% 0.72 Top 27%

B Novelty 12% 0.68 Top 69%

B Feasibility 12% 0.60 Top 45%

B Impact 12% 0.65 Top 59%

C+ Druggability 10% 0.58 Top 55%

B Safety Profile 8% 0.62 Top 34%

B+ Competition 6% 0.72 Top 41%

C+ Data Availability 5% 0.55 Top 61%

B Reproducibility 5% 0.65 Top 40%

Evidence

3 supporting | 1 opposing

Citation quality: 0%

Debates

1 session B

Avg quality: 0.69

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

What are the conserved secondary structures in dilncRNAs that enable selective therapeutic targeting?

The ASO therapeutic hypothesis assumes dilncRNAs have targetable conserved structures, but the skeptic noted this is unproven. Without structural characterization, sequence-specific targeting remains speculative and could affect off-target RNAs. Source: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062229-35a642ca (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062229-35a642ca)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

MALAT1 Three-Way Junction as a Druggable Target for Structure-Selective ASOs

Score: 0.583 | Target: MALAT1

Conserved G-Quadruplex Forming Potential in HOTAIR Defines Therapeutic Window

Score: 0.560 | Target: HOTAIR

Structured Intronic Scaffold Regions in Enhancer-dilncRNAs Enable Cell-Type Selective Targeting

Score: 0.489 | Target: ECEPs (PAX6-AS1, KCNC2-AS1)

A-Tract Bulge Conserved Motifs Enable Selective Targeting of NEAT1 Subdomains

Score: 0.413 | Target: NEAT1

→ View full analysis & all 5 hypotheses

Description

NORAD's evolutionarily conserved 5' stem-loop (nt 1-180) scaffolds multiple PUMILIO binding motifs in a structured context. Selective ASO targeting releases PUMILIO repression of mitotic genes (CHEK1, TOP2A, KIF15), restoring genomic stability. Among proposed targets, NORAD has the strongest primary evidence for structural conservation across primates and rodents (Tichon et al., 2016) and demonstrates clear mechanistic link between structure and function (PUMILIO binding requires structured NORAD regions).

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

4 citations 4 with PMID Validation: 0% 3 supporting / 1 opposing

✓ For (3)

No supporting evidence

No opposing evidence

(1) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 3CLIN 0GENE 1EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
NORAD is one of the most conserved lncRNAs between…	Supporting	MECH	-	-	-	-	PMID:27104844	-
PUMILIO binding requires structured NORAD regions	Supporting	MECH	-	-	-	-	PMID:29686389	-
NORAD knockout leads to mitotic catastrophe	Supporting	GENE	-	-	-	-	PMID:27104844	-
Conservation limited to 5' region; internal r…	Opposing	MECH	-	-	-	-	PMID:27104844	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 3

NORAD is one of the most conserved lncRNAs between human and mouse

PMID:27104844

PUMILIO binding requires structured NORAD regions

PMID:29686389

NORAD knockout leads to mitotic catastrophe

PMID:27104844

✗ Opposing Evidence 1

Conservation limited to 5' region; internal repeats are poorly conserved

PMID:27104844

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-21 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Therapeutic Hypotheses: Conserved Structural Features in dilncRNAs for ASO Targeting

Hypothesis 1: Conserved Triple Helix (Three-Way Junction) Motifs in MALAT1 as Druggable Targets

Title: The MALAT1 triple helix domain represents a conserved structural scaffold amenable to stereochemistry-blocked ASO targeting

Mechanism: The triple helix motif at the MALAT1 3' end (nt 5311-5331) forms a conserved three-way junction that is essential for nuclear speckle localization and interaction with TRA2B/PTBP1. Disruption of this structure using structure-selective ASOs would destabili

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of dilncRNA Structural Therapeutic Hypotheses

Hypothesis 1: MALAT1 Triple Helix (Confidence 0.78 → Revised: 0.45)

Weak Links:

Nomenclature confusion: "Three-way junction" ≠ "triple helix." Triple helix (triplex) structures involve Hoogsteen-bonded third strands invading duplex regions. The MALAT1 A-rich motif forms a three-way junction (a stem-loop with internal loops), not a triplex. Mislabeling the target structure undermines mechanism clarity.
Overstated conservation: Brown et al. (2014) demonstrated conservation in mammals, but Liu et al. (

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Feasibility Assessment: Conserved Structural Features in dilncRNAs for ASO Targeting

Executive Summary

The skeptic's core objection—unproven structural conservation enabling selective targeting—is scientifically valid but not necessarily fatal. Five structural hypotheses survive initial scrutiny with revised confidence scores, though only 2-3 warrant immediate preclinical investment. The central feasibility question shifts from "Are these structures conserved?" to "Does structure-selective targeting offer advantages over full-transcript knockdown?"